ARS Pharmaceuticals, a pharmaceutical company, specializing in anti-allergy drugs, agreed to merge with Silverback Therapeutics, a biopharmaceutical company, in a $144m deal. “We are extremely pleased to announce this proposed merger with Silverback, which we believe enables ARS to maximize the paradigm-changing opportunity of neffy. neffy is on the cusp of achieving what has not been possible before – the ability to deliver epinephrine with comparable pharmacokinetics to an intramuscular injection, but with a simple to administer nasal spray. We have completed a comprehensive registration program with neffy and based on a favorable pre-NDA meeting with the US Food and Drug Administration, we are preparing to submit our New Drug Application in the third quarter of 2022. This merger positions ARS and our experienced team to execute on the potential launch of neffy in 2023 by providing the requisite capital needed for launch,” Richard Lowenthal, ARS Co-Founder and CEO.